PF 04217903 mesylate

Biological Activity

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Additional Information

Background References

1. Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers.
   Khelwatty S, Essapen S, Seddon A, Fan Z, Modjtahedi H
   Br J Cancer, 2015;113(7):1010-9.
2. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
   Eder et al.
   Clin.Cancer Res., 2009;15:2207
3. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
   Timofeevski et al.
   Biochemistry, 2009;48:5339
4. Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates.
   Underiner et al.
   Anticancer Agents Med.Chem., 2010;10:7
5. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-
   Cui et al.
   J.Med.Chem., 2012;55:8091

Product Datasheets